Misako Nagasaka, MD, PhD

Misako Nagasaka, MD, PhD, is associate professor in the Division of Hematology and Oncology and the Division of Medicine at the University of California Irvine School of Medicine.

Articles by Misako Nagasaka, MD, PhD

Recent Advances in Treatment of MET Exon 14 Skipping Mutations in NSCLC

ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD

May 5th 2022

Dr Martin Dietrich provides an overview of how to treat MET exon 14 skipping mutations in non–small cell lung cancer.

Updates in Treatment of HER2 Mutant NSCLC

ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD

May 5th 2022

Dr Misako Nagasaka reviews clinical trial data presented at ESMO 2021 on therapies for NSCLC harboring HER2 exon 20 mutations.

Recent Advances in Treatment of EGFR Exon 20 Insertion Mutations in NSCLC

ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD

May 2nd 2022

Dr Fernando Santini explains EGFR exon 20 insertion mutations in NSCLC and the best approaches for treating these cases.

Updates in Treatment of NSCLC with Classical EGFR Mutations

ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD

May 2nd 2022

A discussion on EGFR mutations in non-small cell lung cancer and the combination treatment strategies for sensitizing mutations.

Challenges Associated with Molecular Testing in NSCLC

ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD

April 19th 2022

A look at the challenges associated with different molecular testing methods and the barriers that patients with non–small cell lung cancer face in getting tested.

Molecular Testing in NSCLC: What is the Optimal Sample and Time of Testing?

ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD

April 19th 2022

A panel of thought leaders describe the optimal sample to use in molecular testing in NSCLC and the appropriate time to perform testing in clinical practice.

Liquid Biopsies in the NSCLC Molecular Testing Algorithm

ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD

April 12th 2022

Experts in lung cancer explain their views on the critical role of liquid biopsy in molecular testing in non–small cell lung cancer.

Testing Approaches for Actionable Mutations in NSCLC in Clinical Practice

ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD

April 12th 2022

Oncologists provide insight into what actionable mutations they look for when they order molecular testing for patients with advanced non-small cell lung cancer.

Misako Nagasaka, MD, PhD

Articles by Misako Nagasaka, MD, PhD

Recent Advances in Treatment of MET Exon 14 Skipping Mutations in NSCLC

Updates in Treatment of HER2 Mutant NSCLC

Recent Advances in Treatment of EGFR Exon 20 Insertion Mutations in NSCLC

Updates in Treatment of NSCLC with Classical EGFR Mutations

Challenges Associated with Molecular Testing in NSCLC

Molecular Testing in NSCLC: What is the Optimal Sample and Time of Testing?

Liquid Biopsies in the NSCLC Molecular Testing Algorithm

Testing Approaches for Actionable Mutations in NSCLC in Clinical Practice

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma